Equities analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will post $570,000.00 in sales for the current quarter, Zacks reports. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. The highest sales estimate is $1.16 million and the lowest is $50,000.00. Ascendis Pharma A/S reported sales of $1.13 million during the same quarter last year, which indicates a negative year-over-year growth rate of 49.6%. The firm is expected to issue its next earnings report on Wednesday, March 28th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year sales of $570,000.00 for the current year, with estimates ranging from $1.97 million to $2.00 million. For the next fiscal year, analysts expect that the company will post sales of $2.52 million per share, with estimates ranging from $940,000.00 to $5.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, November 16th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.37). Ascendis Pharma A/S had a negative return on equity of 64.10% and a negative net margin of 4,687.42%.
Several brokerages have recently issued reports on ASND. Bank of America increased their price objective on Ascendis Pharma A/S from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. BidaskClub upgraded Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. HC Wainwright reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, January 19th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $60.00 price objective on shares of Ascendis Pharma A/S in a research note on Wednesday, January 17th. Finally, Zacks Investment Research cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $43.29.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded down $2.17 during midday trading on Friday, hitting $51.50. The stock had a trading volume of 220,308 shares, compared to its average volume of 183,625. Ascendis Pharma A/S has a twelve month low of $21.05 and a twelve month high of $55.00.
Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new position in Ascendis Pharma A/S in the third quarter valued at $7,163,000. RA Capital Management LLC increased its holdings in Ascendis Pharma A/S by 3.2% in the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock valued at $154,920,000 after buying an additional 170,700 shares during the last quarter. California Public Employees Retirement System purchased a new position in Ascendis Pharma A/S in the second quarter valued at $430,000. Jane Street Group LLC purchased a new position in Ascendis Pharma A/S in the third quarter valued at $352,000. Finally, Janus Henderson Group PLC purchased a new position in Ascendis Pharma A/S in the second quarter valued at $15,403,000. 78.93% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/30/ascendis-pharma-a-s-asnd-expected-to-announce-quarterly-sales-of-570000-00.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.